LEBRIKIZUMAB
Information current as at: 1 August 2025
The pharmaceutical company has advised that it is not proceeding in the PBS listing process at this time. The process for listing this medicine has ceased.
Submission Details
- Brand name:
-
- Ebglyss®
- Pharmaceutical company:
- Eli Lilly Australia Pty Ltd
- Condition/indication:
(therapeutic use) -
- Atopic dermatitis
- PBAC Submission type:
- New PBS listing (Category 2)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – March 2024
- Related medicines:
- --
Progress Details
-
Submission received for: - March 2024 PBAC meeting
-
Opportunity for consumer comment: - Open 22/11/2023 and close 31/01/2024 (see PBS Website)
-
PBAC meeting: - Held on 13/03/2024
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Awaiting lodgement from pharmaceutical company
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a833
Page last updated: 30 June 2025